Talquetamab治疗复发难治多发性骨髓瘤的真实世界评估
国际骨髓瘤工作组免疫治疗登记处开展首个真实世界研究,纳入五国151例复发难治多发性骨髓瘤患者,中位随访12.7个月。结果显示总缓解率67.6%,中位无进展生存7个月,12个月总生存率65%;黏膜皮肤毒性常见但≥3级少见,仅血小板<50与较差无进展生存相关。
要点
- 真实世界中Talquetamab总缓解率67.6%,中位无进展生存7个月。
- 指甲毒性75.5%、口腔毒性62.9%、味觉障碍60.4%,≥3级≤4%。
- 仅血小板<50与较差无进展生存独立相关(HR 1.8)。
核心结论
- Talquetamab在重度经治、高BCMA暴露的真实世界人群中仍保持疗效。
研究设计与样本
- 国际骨髓瘤工作组免疫治疗登记处真实世界分析,纳入五国151例复发难治多发性骨髓瘤患者。
主要发现
- 中位随访12.7个月,总缓解率67.6%,中位无进展生存7个月,12个月总生存率65%。
- 皮肤毒性39.7%、指甲毒性75.5%、味觉障碍60.4%、口腔毒性62.9%,≥3级事件≤4%。
- 多因素分析仅血小板<50与较差无进展生存相关(HR 1.8,95%CI 1.15-2.83)。
关键数值与推荐
- 总缓解率67.6%,中位无进展生存7个月,12个月总生存率65%。
- 皮肤毒性剂量中断9.6%,味觉障碍6.9%,口腔毒性4.0%。
临床怎么用
- 真实世界用药需加强黏膜皮肤毒性支持治疗,关注血小板<50患者预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real-world study to comprehensively report muco-cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow-up reported enabling better efficacy and toxicity estimates. The median age was 64 years; high-risk cytogenetics were present in 42%; ECOG ≥ 2 in 22%; 12% had creatinine clearance < 30; and 55% would not have met MonumenTAL-1 eligibility. Patients received a median of 6 prior lines of therapy, 53% were penta-refractory, and 75% received prior BCMA therapy. Talquetamab was associated with skin toxicity in 39.7%, nail toxicity in 75.5%, dysgeusia in 60.4%, and oral toxicities in 62.9%, with grade ≥ 3 events uncommon (≤ 4%) and dose interruptions infrequent (9.6% for skin toxicity, 6.9% for dysgeusia, and 4.0% for oral toxicities). These findings underscore the need for improved supportive care for muco-cutaneous toxicities. In multivariate analysis, only platelet count < 50 (HR 1.8, 95% CI 1.15-2.83) was associated with inferior PFS, while penta-refractory status, absolute lymphocyte count < 0.4, and prior BCMA-targeted therapy were not statistically significant. With a median follow-up of 12.7 months, the overall response rate was 67.6%, median progression-free survival was 7 months, and 12-month overall survival was 65%. This study shows that talquetamab efficacy is maintained in a heavily pretreated real-world population with high prior BCMA exposure and notable comorbidity burden.
引用
- Janakiram M, Tan CR, Mian H, et al. Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis. Am J Hematol. 2026. PMID: 42157444. doi:10.1002/ajh.70376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。